A. DURAK Et Al. , "A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats," CARDIOVASCULAR DIABETOLOGY , vol.17, 2018
DURAK, A. Et Al. 2018. A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats. CARDIOVASCULAR DIABETOLOGY , vol.17 .
DURAK, A., OLĞAR, Y., Degirmenci, S., AKKUŞ, E., TUNCAY, E., & Turan, B., (2018). A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats. CARDIOVASCULAR DIABETOLOGY , vol.17.
DURAK, AYŞEGÜL Et Al. "A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats," CARDIOVASCULAR DIABETOLOGY , vol.17, 2018
DURAK, AYŞEGÜL Et Al. "A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats." CARDIOVASCULAR DIABETOLOGY , vol.17, 2018
DURAK, A. Et Al. (2018) . "A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats." CARDIOVASCULAR DIABETOLOGY , vol.17.
@article{article, author={AYŞEGÜL DURAK Et Al. }, title={A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats}, journal={CARDIOVASCULAR DIABETOLOGY}, year=2018}